OR WAIT null SECS
February 04, 2022
pharmasol has completed the strategic merger with PharmaLex.
February 02, 2022
Eli Lilly and Company has entered into a research and collaboration agreement with Entos Pharmaceuticals to develop new therapeutics for treating neurologic disorders.
February 01, 2022
Arranta Bio will use Cytiva’s FlexFactory single-use manufacturing platform to produce mRNA vaccines.
Recipharm will build up its biologics service offering with the acquisition of GenIbet.
January 28, 2022
Samsung Biologics has signed an agreement with Biogen to acquire Biogen’s 50% stake in Samsung Bioepis, a joint venture formed by the two companies, for up to $2.3 billion.
PhoreMost has entered into separate collaboration agreements with Polaris Quantum Biotech and NeoCura Bio-Medical Technology to discover and develop novel cancer therapeutics.
BenchSci, a specialist in machine learning applications for novel medicine development, has completed a Series C financing round.
Scottish biotech engineering company, uFraction8, has successfully secured more than £2.5 million ($3.3 million) in new investment.
January 27, 2022
A collaboration and licensing agreement has been entered into by the Queen’s University Belfast and Ipsen.
Stevanato Group has extended its licensing agreement with Haselmeier for its Axis-D pen injector technology.